http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
( Sang Jun Suh ),( Hyung Joon Yim ),( Ji Hye Seo ),( Han Ah Lee ),( Tae Hyung Kim ),( Young Sun Lee ),( Jong Jin Hyun ),( Young Kul Jung ),( Ji Hoon Kim ),( Yeon Seok Seo ),( Jong Eun Yeon ),( Kwan So 대한간학회 2017 춘·추계 학술대회 (KASL) Vol.2017 No.1
Aims: Sorafenib is the standard treatment for advanced hepatocellular carcinoma (HCC). However, the influence of sorafenib on the replication of HBV remains unknown. Herein, we evaluated the rate of HBV reactivation during sorafenib therapy in chronic hepatitis B (CHB) patients with advanced HCC. Methods: Four hundreds thirty five advanced HCC patients who visited three hospitals affiliated with Korea University from January 2004 to December 2012 were retrospectively reviewed. Among them, 327 patients were HBsAg positive. Two hundred sixty four received antiviral therapy before initiation of sorafenib therapy, and 64 patients were treatment naive with regard to anti-HBV therapy. Patients who received sorafenib less than 4 weeks, those who had not follow-up HBV DNA value, and patients who received other treatment than sorafenib were excluded. Finally, 133 and 28 patients were analyzed, respectively in each group. HBV reactivation were defined as increase of HBV DNA >10 times of baselines or ≥ 2000 IU/mL in patients with baselines HBV DNA < 2000 IU/mL. We further investigated reactivation rates in propensity score matched liver cirrhosis patients without HCC. Results: Mean age was 54.87±9.34 and 83.2% were male. All patients were Barcelona Clinic of Liver Cancer Stage C and the sum of tumor diameter was 10.42±5.78 cm. Mean baseline HBV DNA level was 2.84±1.60 log IU/mL. Median survival was 5.97 months. At 12, 24, and 48 weeks of the sorafenib therapy, HBV reactivation occurred in 5.26%, 12.0%, 14.3% of antiviral therapy group while it developed in 28.6%, 39.3%, and 42.9% of HBV therapy naïve group, respectively. The reactivation rates was significantly higher in patient who didn’t received antiviral therapy (p = 0.001). The antiviral therapy (HR 0.250, C.I. 0.104-0.604, p = 0.002) was independent factor related to HBV reactivation by logistic regression analysis. When the 28 HBV therapy naive HCC patients who received sorafenib were compared with propensity score matched 84 HBV therapy naïve liver cirrhosis patients without HCC, the cumulative reactivation rates were also significantly higher in the former group by log-rank test (p <0.001). Conclusions: The risk of HBV reactivation is high in CHB patients receiving sorafenib due to advanced HCC. It would be necessary to administer pre-emptive antiviral therapy before sorafenib initiation.
Han Sung Choi,정경희,이승철,임성빈,Joo-Ho Chung,김윤화,정주호,홍훈표,Young Gwan Ko,김철호,장기효,Soon Ah Kang 한국식품영양과학회 2009 Journal of medicinal food Vol.12 No.1
This study evaluated whether or not bovine colostrum (BC) is able to treat or prevent intestinal barrier damage, bacterial translocation, and the related systemic inflammatory response syndrome (SIRS) and multiple organ dysfunction syndrome (MODS) in an intestinal ischemia/reperfusion (I/R)-injured rat model. Fifty Sprague-Dawley rats were used. The rats' intestinal I/R injuries were induced by clamping the superior mesenteric artery for 30 minutes. After 3 hours of reperfusion and then twice daily reclamping during the experiment, the experimental group was given BC (4 mL/kg/day) perorally, and the other groups received 0.9% saline and low fat milk (LFM) after intestinal I/R injury. Seventy-two hours later we assessed (1) intestinal damage and intestinal permeability, (2) enteric bacterial count and bacterial translocation, (3) serum albumin, protein, and hepatic enzyme levels, (4) pathologic findings of ileum and lung, (5) activity of oxygen-free radical species, and (6) pro-inflammatory cytokines (tumor necrosis factor-α and interleukin-1β). Intestinal damage, intestinal permeability, and bacterial translocation to other organs were significantly reduced in rats fed with BC after I/R when compared to rats fed LFM/saline after I/R (P < .05). In the evaluation of acute lung injury, neutrophils were found only in the lungs of the saline-fed group after I/R, and the wet/dry ratio of the lung tissue was significantly reduced in the BC-fed group after I/R compared to other I/R groups. A marked difference was found between LFM/saline-fed groups and BC-fed groups regarding malondialdehyde (P < .05) and pro-inflammatory cytokines (P < .01). In conclusion, BC may have beneficial effects in treating and preventing intestinal barrier damage, bacterial translocation and the related SIRS and MODS in the intestinal I/R-injured rat model.
Han, Sung-Hee,Heo, Yun-Ah,Yang, Young-Ho,Kim, Young-Jin,Cho, Han-Ik,Lee, Kyoung-Ryul Korean Society of Medical Genetics and Genomics 2012 대한의학유전학회지 Vol.9 No.2
Purpose: Fragile X carrier detection before or at early pregnancy through a wide screening program may not only confer a risk of having offspring with Fragile X syndrome (FXS), but may also confer a risk for Fragile X-associated primary ovarian insufficiency and Fragile X-associated tremor/ataxia syndrome. However, prior to the implementation of such a program, the carrier prevalence in a population and the availability of effective screening test should be evaluated. The aim of our study was to determine the prevalence of premutation carriers and to evaluate the feasibility of screening test. Materials and Methods: The blood samples were obtained from 8,641 pregnant women with no family history of mental retardation. We performed a three-primer CGG repeat primed (RP) PCR using the AmplideX$^{TM}$ FMR1 PCR kit (Asuragen, Inc. Austin, TX, USA). Samples showing full mutation alleles were reflexed to Southern blot analysis for methylation status and sizing. Results: Among the 8,641 women, we found 8 premutation carriers (1:1,090, 0.09%) and 46 women with an intermediate allele (1:190, 0.53%). No woman was found to carry the fully mutated allele. All the detected alleles were within the CGG repeat range of 8-117. Among the 8,641 samples, 29 and 30 CGG repeats represent 66.6% of all cases. The CGG RP PCR method provides robust detection of expanded alleles and resolves allele zygosity, thus minimizing the number of samples that require Southern blot analysis. Conclusion: This is the first study that has focused on the prevalence of FXS premutation carriers and FMR1 allele distribution in normal pregnant women. These data have important implications for population-based fragile X carrier screening in Korea.
Cystatin C is Better than Creatinine for Predicting Prognosis in Cirrhotic Patients with Sarcopenia
( Han Ah Lee ),( Seung Woon Park ),( Sang Jung Park ),( Tae Hyung Kim ),( Sang Jun Suh ),( Young Kul Jung ),( Ji Hoon Kim ),( Hyung Joon Yim ),( Jong Eun Yeon ),( Kwan Soo Byun ),( Soon Ho Um ),( Yeon 대한간학회 2016 춘·추계 학술대회 (KASL) Vol.2016 No.1
Aims: Recent studies suggested that serum cystatin C (CysC) is a better prognostic marker than serum creatinine (Cr) for predicting prognosis in patients with liver cirrhosis. Overestimation of renal function by serum Cr in these patients is associated with decreased muscle mass, which is represented by sarcopenia. This study was performed to evaluate the effect of sarcopenia on the prognostic efficacy of serum Cr and CysC levels in patients with liver cirrhosis. Methods: Cirrhotic patients who performed abdominal CT and serum Cr and CysC levels were enrolled. Patients with hepatocellular carcinoma and parenchymal renal disease were excluded. At evaluation, transverse psoas muscle thickness (TMPT) was measured on a CT image at the level of the umbilicus. Sarcopenia was defined as TPMT/height <16.8 mm/m. Results: A total of 245 patients were enrolled. Age was 55.0±10.2 years and 159 patients (64.9%) were men. Child-Pugh grade was A, B, and C in 121 (49.4%), 68 (27.8%), and 56 (22.9%) patients, respectively. Sarcopenia was noted in 110 patients (44.9%): 33.9%, 55.9%, and 55.4% in patients with Child-Pugh grade A, B, and C, respectively (P=0.003). Cr level were significantly lower in patients with sarcopenia compared to those without sarcopenia (0.7±0.2 vs 0.8±0.2 mg/dL, P<0.001), while CysC level did not (1.0±0.2 vs 1.0±0.3 mg/L, P=0.970). During 23.3±26.1 months of follow-up, 32 patients (13.1%) died. CysC level was significantly associated with survival of both patients with sarcopenia (P<0.001) and those without sarcopenia (P<0.001), while Cr level was not significantly associated with survival of patients with sarcopenia (P=0.760). Conclusions: Serum Cr level was not useful for predicting prognosis in cirrhotic patients with sarcopenia, while CysC level was significantly associated with mortality regardless of the presence of sarcopenia. Serum CysC level is a better option for predicting prognosis in patients with cirrhosis, especially in those with sarcopenia.
( Han Ah Lee ),( Seung Woon Park ),( Sang Jung Park ),( Tae Hyung Kim ),( Sang Jun Suh ),( Young Kul Jung ),( Ji Hoon Kim ),( Hyung Joon Yim ),( Jong Eun Yeon ),( Kwan Soo Byun ),( Soon Ho Um ),( Yeon 대한간학회 2016 춘·추계 학술대회 (KASL) Vol.2016 No.1
Aims: Definite guideline for stopping antiviral therapy for chronic hepatitisB (CHB) is not clarified yet. Previous studies suggested thatHBsAg titer is correlated with covalently closed circular DNA.Therefore, HBsAg titer might be a good indicator for off-treatment.This study was performed to determine the relationship betweenHBsAg titer and CHB relapse after off-treatment of entecavir (ETV).Methods: Patients in whom ETV was discontinued after serum HBVwith or without HBeAg clearance for more than 12 months andwho measured HBsAg titer at off-treatment were enrolled. HBV DNAreactivation was defined as increase of serum HBV DNA level >2000IU/mL, while CHB relapse was defined as HBV DNA reactivation andincrease of serum ALT level >2XULN.Results: Forty-four patients were enrolled. Age was 44.6±11.4 yearsand 28 patients (63.6%) were men. Baseline HBeAg was positive25 patients (56.8%) and serum HBV DNA level was 6.8±1.3 log10IU/mL. ETV was discontinued after 34.7±19.0 months of treatment.In HBeAg-positive CHB patients, ETV was discontinued after37.0±20.2 months of treatment, which was 31.0±19.5 and23.4±16.1 months after serum HBV DNA and HBeAg clearance,respectively. In HBeAg-negative CHB patients, ETV was discontinued after 31.6±17.4 months of treatment, which was 27.1±17.7 monthsafter serum HBV DNA clearance. HBsAg titer at off-treatment was3.0±1.0 log10 IU/mL, which was <2, 2~3, and >3 log10 IU/mL in5 (11.4%), 11 (25.0%), and 28 (63.6%) patients, respectively. Afteroff-treatment, HBV DNA reactivated in 38.7% and 66.2% and CHBwas relapsed in 4.7% and 42.3% at 6 and 12 months after off-treatment,respectively. HBsAg titer at off-treatment was significantly associatedwith HBV DNA reappearance (P=0.010) and CHB relapse(P=0.010).Conclusions: HBsAg titer at off-treatment is closely related with HBVreactivation and CHB relapse. HBsAg titer is considered as an excellentindicator of durable viral response after off-treatment.
( Sang Hyun Kim ),( Han Ah Lee ),( Seung Woon Park ),( Kang Won Lee ),( Young Ho Seo ),( Jae Hoon Kim ),( Sung Jae Choi ),( Young Ho Lee ),( Jong Dae Ji ),( Gwan Gyu Song ) 대한류마티스학회 2016 대한류마티스학회지 Vol.23 No.1
Sjogren’s syndrome (SS) is a chronic autoimmune disorder characterized by lymphocyte-mediated destruction of exocrine glands, which produces classical symptoms of dry eyes and dry mouth. Aside from the clinical manifestations associated with exocrine glands, extraglandular features of SS include a major long-term concern for development of lymphoma. The lifetime risk of non-Hodgkin’s lymphoma (NHL) in an SS patient is approximately 5% to 10%, 20 times higher than that of the normal population. This case report describes a rare occurrence of NHL in the eyelid and lung of an adolescent female with SS, whose disease activity had been monitored closely. This is the first reported case in Korea. (J Rheum Dis 2016;23:61-65)